Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice

Abstract

The cytokine G-CSF stimulates myeloid progenitors and is routinely used to accelerate neutrophil recovery in the treatment of hematological malignancy and blood or marrow transplantation. Despite significant reductions in the frequency and duration of febrile neutropenia episodes, infections and the length of hospitalization, filgrastim has never been conclusively proven to produce a survival benefit in allogeneic HSCT and is considered a supportive measure. In this review, we analyze the conflicting evidence and appraise the utility of G-CSF in allogeneic HSCT. G-CSF administration after allogeneic HSCT needs to take into consideration the impact on immune reconstitution, risk of leukemic progression in patients with chromosome 7 abnormalities and the absence of proven benefit in patients receiving marrow or peripheral blood progenitors as the stem cell source.

DOI: 10.1038/bmt.2008.443

1 Figure or Table

Statistics

0200400200920102011201220132014201520162017
Citations per Year

544 Citations

Semantic Scholar estimates that this publication has 544 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Battiwalla2009FilgrastimSI, title={Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice}, author={Minoo Battiwalla and P L McCarthy}, journal={Bone Marrow Transplantation}, year={2009}, volume={43}, pages={351-356} }